Total Payments
$96,976
2024 Payments
$22,389
Companies
6
Transactions
30
Medicare Patients
791
Medicare Billing
$110,517
Payment Breakdown by Category
Research$70,441 (72.6%)
Consulting$21,233 (21.9%)
Travel$4,792 (4.9%)
Food & Beverage$494.74 (0.5%)
Education$16.53 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $70,441 | 6 | 72.6% |
| Consulting Fee | $21,233 | 9 | 21.9% |
| Travel and Lodging | $4,792 | 6 | 4.9% |
| Food and Beverage | $494.74 | 8 | 0.5% |
| Education | $16.53 | 1 | 0.0% |
Payments by Type
Research
$70,441
6 transactions
General
$26,536
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $79,583 | 13 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $17,214 | 13 | $0 (2024) |
| Foundation Medicine, Inc. | $107.47 | 1 | $0 (2017) |
| Novo Nordisk Health Care AG | $40.50 | 1 | $0 (2021) |
| Agios Pharmaceuticals, Inc. | $16.53 | 1 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.18 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,389 | 18 | Alexion Pharmaceuticals, Inc. ($14,734) |
| 2023 | $70,025 | 5 | NOVARTIS PHARMACEUTICALS CORPORATION ($67,545) |
| 2022 | $4,400 | 4 | Novartis Pharmaceuticals Corporation ($4,400) |
| 2021 | $40.50 | 1 | Novo Nordisk Health Care AG ($40.50) |
| 2018 | $14.18 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($14.18) |
| 2017 | $107.47 | 1 | Foundation Medicine, Inc. ($107.47) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $26.94 | General |
| Category: Rare Disease | ||||||
| 11/09/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $63.00 | General |
| 11/08/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $9,610.00 | General |
| 11/08/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $84.99 | General |
| 11/08/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $76.05 | General |
| 11/08/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $64.98 | General |
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $4,076.13 | General |
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $456.86 | General |
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $135.00 | General |
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $69.10 | General |
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $50.59 | General |
| 10/16/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Education | In-kind items and services | $16.53 | General |
| Category: Genetically Defined Disease | ||||||
| 09/23/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Consulting Fee | Cash or cash equivalent | $742.50 | General |
| Category: Immunology | ||||||
| 08/01/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $3,095.39 | Research |
| Study: HEOR | ||||||
| 04/30/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | — | Cash or cash equivalent | $1,962.85 | Research |
| Study: HEOR • Category: Immunology | ||||||
| 02/28/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: Rare Disease | ||||||
| 01/29/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| 01/01/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,312.50 | General |
| 11/13/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| 09/08/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 08/02/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $2,480.00 | General |
| Category: Rare Disease | ||||||
| 05/09/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 01/02/2023 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $63,870.33 | Research |
| Study: Cost to Treat Newly Diagn Patients with Paroxysmal Patients with PNH in Nocturnal Hemoglobinuria in the US | ||||||
| 08/02/2022 | Novartis Pharmaceuticals Corporation | — | — | In-kind items and services | $504.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | ||||||
| 08/02/2022 | Novartis Pharmaceuticals Corporation | — | — | In-kind items and services | $504.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Cost to Treat Newly Diagn Patients with Paroxysmal Patients with PNH in Nocturnal Hemoglobinuria in the US | Novartis Pharmaceuticals Corporation | $63,870 | 1 |
| HEOR | Novartis Pharmaceuticals Corporation | $5,058 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $1,512 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 95 | 119 | $77,480 | $12,537 |
| 2022 | 5 | 245 | 341 | $201,565 | $37,144 |
| 2021 | 6 | 244 | 345 | $171,896 | $36,870 |
| 2020 | 4 | 207 | 271 | $104,517 | $23,966 |
Total Patients
791
Total Services
1,076
Medicare Billing
$110,517
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 45 | 56 | $35,049 | $5,994 | 17.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 51 | $32,771 | $4,780 | 14.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $9,660 | $1,762 | 18.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 96 | 153 | $97,780 | $17,003 | 17.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 70 | 96 | $58,289 | $11,389 | 19.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 22 | $17,486 | $3,725 | 21.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 35 | $14,299 | $3,067 | 21.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 22 | $12,047 | $1,602 | 13.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 12 | 13 | $1,664 | $357.84 | 21.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 74 | 107 | $56,083 | $13,211 | 23.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 68 | 109 | $61,620 | $12,583 | 20.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 23 | 23 | $18,795 | $4,012 | 21.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 38 | $16,150 | $3,418 | 21.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 21 | 25 | $8,050 | $1,500 | 18.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 11 | $4,115 | $904.35 | 22.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 14 | 15 | $4,830 | $760.94 | 15.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 12 | 17 | $2,253 | $480.76 | 21.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 29 | 30 | $24,376 | $5,276 | 21.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 46 | 68 | $13,953 | $4,503 | 32.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 52 | 63 | $11,836 | $4,293 | 36.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 27 | 44 | $18,370 | $4,010 | 21.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 28 | 39 | $22,170 | $3,451 | 15.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 25 | 27 | $13,812 | $2,434 | 17.6% |
About Dr. Anem Waheed, MD
Dr. Anem Waheed, MD is a Hematology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2012. The National Provider Identifier (NPI) number assigned to this provider is 1780941567.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anem Waheed, MD has received a total of $96,976 in payments from pharmaceutical and medical device companies, with $22,389 received in 2024. These payments were reported across 30 transactions from 6 companies. The most common payment nature is "" ($70,441).
As a Medicare-enrolled provider, Waheed has provided services to 791 Medicare beneficiaries, totaling 1,076 services with total Medicare billing of $110,517. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Boston, MA
- Active Since 04/18/2012
- Last Updated 03/07/2024
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1780941567
Products in Payments
- Fabhalta (Drug) $2,705
- ULTOMIRIS (Biological) $2,528
- FOUNDATIONONE (Device) $107.47
- PYRUKYND (Drug) $16.53
- GILOTRIF (Drug) $14.18
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Boston
Jacalyn Rosenblatt, M.d, M.D
Hematology — Payments: $1.6M
Hematology $1.6M
Jorge Castillo, Md, MD
Hematology — Payments: $922,724
Hematology $922,724
Dr. Edward Benz, Md, MD
Hematology — Payments: $746,999
Hematology $746,999
Andrew Evens, Do, Ms, DO, MS
Hematology — Payments: $339,696
Hematology $339,696
Dr. Caron Jacobson, Md, MD
Hematology — Payments: $294,282
Hematology $294,282
Lynn Bry, Md, MD
Hematology — Payments: $285,993
Hematology $285,993